Integration of Genomics into Public Policies and Health Services – European Perspectives and Initiatives
“Public Health Genomics (PHG) is the responsible and effective translation of genome-based knowledge and technologies into public policy and health services for the benefit of population health.”

(Bellagio Statement 2005: GRAPHInt, PHGEN)
The Enterprise

Genome-based Science and Technology

Improvement in Population Health

Public Health Genomics European Network (PHGEN) – www.phgen.nrw.de
The Enterprise

Knowledge Generation

Population Sciences

Genome-based Science and Technology

Humanities and Social Sciences

Improvement in Population Health

Public Health Genomics European Network (PHGEN) – www.phgen.nrw.de
The Enterprise

Knowledge Generation

Population Sciences

Genome-based Science and Technology

Humanities and Social Sciences

Knowledge Integration Within And Across Disciplines

Improvement in Population Health

Knowledge Generation

Public Health Genomics European Network (PHGEN) – www.phgen.nrw.de
The Enterprise

Public Health Genomics European Network (PHGEN) – www.phgen.nrw.de
Public Health Genomics (PHG) -
no revolution, but evolution!

“One specific task of PHG is to reconsider and systematically evaluate every condition of public health interest...” , e.g.

- evidence-based (stratified) prevention
- balance between self-responsibility and social welfare
- reduction of (genetic) inequalities in health
- health protection (e.g., recombinant vaccines, bioremediation, enivrongenomics)
- consumer protection (e.g., nutrigenomics)
- health management (e.g., stakeholder responsibilities, public policy, regulation, risk communication, public participation, professional education and training)

Human Genetics (HG), Community Genetics (CG) and Public Health Genomics (PHG) have complementary tasks!

**Basic Research**

- Biotechnology
- Biobanks (Surveillance)
- Clinical Trials

**Medicine (HG)**

- QA (ACCE)
- Use in Clinical Practice
- Genetic Tests
- Biomarkers

**Public Health (PHG)**

- HNA (incl. PHELSI)
- HTA
- HIA/PIA
- Regulation

**Use in Health Systems**

- Use in Health Systems
  - Policy Development
    - Assessment
    - Assurance

**Genome-based Knowledge and Technologies**
The call

The European Commission called for a “networking exercise ... to lead to an inventory report on genetic determinants relevant to public health. This network will identify public health issues linked to current national practices in applying genetic testing and on that basis will contribute to developing best practice in applying genetic testing.”

Community action in the field of public health (2003-2008), Work plan 2005
PHGEN

Public Health Genomics European Network

January 1st 2006 – December 31st 2008 (36 months)

EU Project: 2005313
Aims of PHGEN (1)

• To conduct a networking exercise on PHG covering all EU Member States, Applicant Countries, and EFTA-EEA Countries

• To identify and list key experts and institutions relevant to PHG in these countries

• To provide an inventory of genetic determinants relevant to public health

• To provide an inventory of PHG-issues and priorities in Europe
Aims of PHGEN (2)

• To identify legal diversities and barriers in a cross-border market

• To analyse the relevance of EU treaties for PHG

• To contribute to the co-operation and exchange of information in order to enhance coherence and disseminate best practice in Europe

• To promote and stimulate the countries’ efforts in this emerging field by developing PHGEN and by supporting effective networking in order to reach sustainability (e.g. national task forces on PHG)
In the long run, PHGEN will serve the European Commission as an 'early detection unit' for horizon scanning, fact finding, and monitoring of the integration of genome-based knowledge and technologies into public health.
Main Partner & Associated Partners

Institute of Public Health
NRW (lögd)
Westerfeldstrasse 35-37
33611 Bielefeld
Germany

German Center for Public Health Genomics (DZPHG)
Kurt-Schumacher-Strasse 6
33615 Bielefeld
Germany

Public Health Genetics Unit (PHGU)
Strangeways Research Laboratory
Worts Causeway
Cambridge CB1 8RN
UK
Steering Group

- Angela Brand, German Center for Public Health Genomics, Bielefeld, Germany (Speaker)
- Hilary Burton & Ron Zimmern, Public Health Genetics Unit, Cambridge, UK
- Helmut Brand, Institute of Public Health NRW (lögd), Bielefeld, Germany
- Jean-Jacques Cassiman, Center for Human Genetics, Catholic University Leuven, Belgium
- Bartha Knoppers, Law Faculty, University of Montreal, Canada
- Marcella Rietschel, Central Institute of Mental Health, Mannheim, Germany
- Jörg T. Epplen, Department of Human Genetics, Ruhr-University Bochum, Germany
- Peter Dabrock, Department of Social Ethics, Philipps University Marburg, Germany
- Finn Kristensen, EUnetHTA, Danish Centre for Evaluation and HTA, Copenhagen, Denmark
- Andrej Marusic, Institute of Public Health, Ljubljana, Slovenia
- Dolores Ibarreta, Institute for Prospective Technological Studies (IPTS), Sevilla, Spain
- Ingolf Pernice, Walter Hallstein Institute for European Constitutional Law, Berlin, Germany
Collaborating Partners, Networks, Organizations & Experts

Collaborating Partners from all EU Member States, Applicant Countries, EFTA-EEA Countries:
public health, human genetics, competent authorities

Representatives of EU Networks:
e.g. EuroGentest, EUnetHTA, Orphanet, NuGo

Representatives of Organizations:
e.g. WHO, WTO, OECD, UNESCO, STOA

Experts on European Law

Experts from outside EU:
e.g. CDC, AETMIS, P³G
Public Health Genomics European Network (PHGEN) – www.phgen.nrw.de
Roadmap: 10 Work Packages

1. Project Coordination
2. Evaluation
3. Dissemination
4. Network Meetings
5. Steering Group Meetings
6. Assessment
7. Policy Development
8. Assurance
9. Final Conference
10. Final Report
Assessment (WP6)

Systematic collection, assembly & analysis of genome-based information relevant to Public Health

- Analysis of PHG concepts (e.g. definition of PHG, genetic determinants, risk stratification)
- Identification of PHG issues & priorities
- Identification and „best practice“ of PH methods relevant to PHG (e.g. HNA, HTA, HIA/PIA)
- Identification of networks and institutions relevant to PHG

→ Assessment Paper
Policy Development (WP7)

Developing European standards and guidelines which promote the responsible and effective use of genome-based information and technologies in European health systems

- Analysis of legal diversities (e.g. conflicting laws) and barriers in a cross-border market
- Analysis of EU treaties for PHG
- Analysis of European minimal standards, guidelines & laws
- Analysis of economic implications & PHELSI
- Development of policies on education, information and empowerment

➡️ Policy Development Paper
Assurance (WP8)

Appropriate use of genome-based information and technologies in European health services

- Need for enforcement of new laws and/or regulations?
- Assurance of stakeholders´ responsibilities in the application of genome-based information and technologies
- Assurance of a competent workforce
- Evaluation of health services (e.g. health promotion, disease prevention, therapy, rehabilitation)

⇒ Assurance Paper
PHGEN, EGAN & Eastern European Countries: challenges I/II

• Involvement of EGAN in PHGEN II?

• Involvement of representatives of EECs as CPs in PHGEN since 1/2006

• Development of European policies supporting national policies: eg. patient rights in biobanks

• Implementation of responsible, effective and efficient health services: from a prospective perspective in EECs versus from a retrospective perspective in Western European Countries (WECs) (innovation versus imitation)
PHGEN, EGAN & Eastern European Countries: challenges II/II

- Use of already existing strong infrastructures in EECs: e.g. Institutes of Public Health (IPHs)
- Implementation of EU regulations barriers regarding “Tourism on genome-based health services“ from WECs to EECs
Group Ponders Genomics and Public Health

Xavier Bosch, MD, PhD

The European Union (EU) has launched a new project to ensure that public health systems exploit advances in genetics, the rights of individuals are protected. The Public Health Genomics European Network (PHGEN) "will not only identify where and how the EU has to approach challenges and changes posed by public health genomics but will also give concrete recommendations on how genome-based knowledge can responsibly and effectively be integrated into public health," said Helmut Brand, MD, MSc, project leader and director of the Institute of Public Health of Nordrhein-Westfalen, in Bielefeld, Germany. The PHGEN is essentially run by the Institute, the German Center for Public Health Genomics (also in Bielefeld), and the Public Health Genetics Unit, in Cambridge, England.

To date, public health policies and practices have mainly dealt with environmental determinants of health and disease, and little attention has been paid to targeting individuals according to their genetic profiles. But knowledge of gene variants that affect an individual’s susceptibility to a disease or response to therapeutic and preventive interventions is fast increasing. For example, the discovery of gene variants that can affect an individual’s risk of developing coronary heart disease make it possible to identify individuals who are at increased risk of developing the condition and to quantify the effect of such variants. However, it’s also important to understand and quantify the importance of modifiable risk factors for coronary heart disease, such as smoking and hypertension. “Based on the knowledge of these attributable risks, sound policies and effective interventions can be made,” said Angela Brand, MPH, PHGEN speaker at the German Center for Public Health Genomics.

The network intends to work out how EU policies apply to advances in public health genomics. “It is a task of PHGEN to identify what regulations, or not yet regulated fields, are relevant to public health genomics,” said Helmut Brand. He added that PHGEN will monitor the integration of genome-based evidence with public health by working with other networks established by the European Commission (EC), including EuroGenTest (which addresses questions about the clinical validity and utility of genetic tests), EUhealthTA (which works on health technology assessment), Orphanet (European network on rare diseases), and NuGo (European network on nutrigenomics).

“We are excited about the European initiative because realizing health benefits from genomic research depends above all on collaborative efforts,” says Minta Gwinn, MD, MPH, of the Office of Genomics and Disease Prevention at the Centers for Disease Control and Prevention in Atlanta.

The EC is providing $1.0 million to fund the project until the end of 2008. At that time, it will consider a second proposal to fund the project for another 3 years. During PHGEN’s first 3 years, 100 experts from 34 countries will provide an inventory of public health genomics issues and priorities in Europe while identifying legal differences and barriers in a cross-border market. “Plus we will work on the institutionalization of public health genomics in the different European countries,” Helmut Brand said.

Speaking at the PHGEN’s first network meeting in February, in Bielefeld, Dolores Ibarreta, PhD, of the EC Joint Research Centre, said that PHGEN may help fill in some gaps in genetic testing in Europe, where pre- and post-conceiving are not always adequate and about half of the laboratories performing genetic testing have never been officially inspected. Besides genetic testing and gene therapy, the PHGEN will assess policy pertaining to pharmaco-genomics and nutrigenomics, recommendations for principles governing biobanks, and practices of preimplantation genetic diagnosis in the EU.

“In a final report, we will make recommendations to the EC, which might then suggest legislation relevant for public health genomics,” said Angela Brand.